Organon & Co. (NYSE:OGN) Holdings Raised by Wells Fargo & Company MN

Wells Fargo & Company MN increased its stake in Organon & Co. (NYSE:OGN) by 28.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 262,746 shares of the company’s stock after purchasing an additional 58,378 shares during the quarter. Wells Fargo & Company MN owned about 0.10% of Organon & Co. worth $3,920,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Barclays PLC raised its holdings in shares of Organon & Co. by 238.0% in the 3rd quarter. Barclays PLC now owns 119,483 shares of the company’s stock worth $2,285,000 after purchasing an additional 84,136 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Organon & Co. in the third quarter valued at $185,000. Optimist Retirement Group LLC acquired a new stake in shares of Organon & Co. in the third quarter worth $1,974,000. Tidal Investments LLC grew its holdings in shares of Organon & Co. by 10.6% during the third quarter. Tidal Investments LLC now owns 76,525 shares of the company’s stock valued at $1,464,000 after buying an additional 7,330 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in Organon & Co. by 3.9% during the third quarter. Franklin Resources Inc. now owns 344,138 shares of the company’s stock valued at $6,229,000 after buying an additional 13,029 shares during the period. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $10.67 on Tuesday. The stock has a market capitalization of $2.75 billion, a P/E ratio of 3.20, a P/E/G ratio of 0.90 and a beta of 0.73. The business has a 50-day moving average of $14.17 and a two-hundred day moving average of $15.32. Organon & Co. has a fifty-two week low of $10.45 and a fifty-two week high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. On average, equities research analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were paid a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 10.50%. Organon & Co.’s payout ratio is presently 33.63%.

Wall Street Analyst Weigh In

A number of brokerages have commented on OGN. Barclays decreased their price objective on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Morgan Stanley dropped their price objective on shares of Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 9th. Finally, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $20.60.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.